Kwangdong Pharmaceutical AI Center Recognized as Corporate Research Institute, Accelerating Company-Wide AI Innovation
Predicted impact: Low
AI center recognized as corporate research institute; small effect.
Kwangdong Pharmaceutical광동제약
009290 · KOSPI · ₩009290 · 광동제약
₩6,360▼ ₩90 (1.40%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y +9.28%
- Market cap
- ₩317B
- Enterprise value
- ₩443B
- P/E
- 14.5×
- P/B
- 0.5×
- Dividend yield
- 1.6%
- ROE
- 3.4%
- Net margin
- 1.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.3% from the high
₩5,150Today: ₩6,290 – ₩6,490₩12,800
Returns
- 1W−4.8%
- 1M−0.5%
- 3M+7.4%
- 6M−26.5%
- YTD+8.5%
- 1Y+9.3%
- Volume today
- 124,145
- 0.8× the 20-day average
- Traded today
- ₩792M
- Listed shares
- 49,799,808
- EPS (12 months)
- ₩438
- Earnings yield 6.9%
AI research · InitiationKwangdong Pharmaceutical: Thin Margins, Low Book Multiple and a Wide Model RangeThe data shows a long-established company with steadily growing sales but persistently thin profitability, modest returns and a leveraged balance sheet.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headlines describe a company expansion of its AI work, which reads as mildly positive. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-0.6% over the last month; the price is below its 20-day average.
- News impactSome5 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Kwangdong Pharmaceutical stock overview
Kwangdong Pharmaceutical (광동제약, KRX: 009290) is listed on KOSPI, in the Biotech & Pharma sector. Kwangdong Pharmaceutical operates in three business segments: over-the-counter pharmacy products, prescription drugs sold through hospitals, and food and beverages. Its shares closed at ₩6,360 on Oct 27, 2026, down 1.40% on the day, giving it a market value of ₩317B.
Key facts
- Market cap
- ₩317B
- Sector
- Biotech & Pharma
- Latest price change
- −1.40%
- As of
- Oct 27, 2026
- Main business
- Kwangdong Pharmaceutical operates in three business segments: over-the-counter pharmacy products, prescription drugs sold through hospitals, and food and beverages.
Quick answers about Kwangdong Pharmaceutical
- What does Kwangdong Pharmaceutical do?
- Kwangdong Pharmaceutical operates in three business segments: over-the-counter pharmacy products, prescription drugs sold through hospitals, and food and beverages. Its main offerings include traditional medicines such as Cheongsimwon, hospital-channel prescription drugs such as vaccines and anticancer treatments, and beverages including Jeju Samdasu mineral water and Vita500. Most of its sales are generated in the domestic market, and it produces products at factories in Pyeongtaek, with some items manufactured under OEM arrangements.
- What is the market cap of Kwangdong Pharmaceutical?
- The market capitalisation of Kwangdong Pharmaceutical was ₩317B at the close on Oct 27, 2026.
- Who are the largest shareholders of Kwangdong Pharmaceutical?
- According to the latest official filings, the largest reported holders are Choi Sung-won (19.42%, as of Oct 12, 2026); Fidelity Management & Research Company LLC (9.99%, as of Feb 19, 2025); Fidelity Low-Priced Stock Fund (7.55%, as of Jul 31, 2026).
- When is the next earnings report from Kwangdong Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Kwangdong Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Kwangdong Pharmaceutical?
- Yes. The National Pension Service held 0.80% of Kwangdong Pharmaceutical shares as of Dec 31, 2025.
Company profile
Kwangdong Pharmaceutical operates in three business segments: over-the-counter pharmacy products, prescription drugs sold through hospitals, and food and beverages. Its main offerings include traditional medicines such as Cheongsimwon, hospital-channel prescription drugs such as vaccines and anticancer treatments, and beverages including Jeju Samdasu mineral water and Vita500. Most of its sales are generated in the domestic market, and it produces products at factories in Pyeongtaek, with some items manufactured under OEM arrangements.
Written by AI from the company's latest annual report.
- Korean name
- 광동제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 최성원, 박상영(각자대표)
- Founded
- Oct 1963
- Listed
- Nov 1989
- Listed shares
- 49,799,808
- Fiscal year ends
- Month 12
- Website
- www.ekdp.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Kwangdong Pharmaceutical Converts In-House AI Dedicated Team into Corporate Research Institute, Expanding Scope of Application
Predicted impact: Low
Internal AI team restructured into research institute; no financial impact.
Kwangdong Pharmaceutical Conveys Environmental Protection Values Through Art, Hosts "Unforgotten Exhibition"
Predicted impact: Medium
Regulatory referral to police over misleading advertising already reported earlier.
Recent filings
See all- 5%+ holding reportOct 12, 2026
- 5%+ holding reportOct 2, 2026
- Change in largest shareholder's holdingsAug 28, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earnings (consolidated)Aug 12, 2026
Titles in Korean until English translations are added.
Also known as: Kwangdong Pharmaceutical / 광동제약 / 009290 / KRX:009290
Source: KRX statistical information